Relationship between Participant-Reported Outcomes, Residual Beta Cell Function, and Metabolic Parameters in Youth with Newly Diagnosed Type 1 Diabetes
Posted inDiabetes & Endocrinology news Pediatrics

Relationship between Participant-Reported Outcomes, Residual Beta Cell Function, and Metabolic Parameters in Youth with Newly Diagnosed Type 1 Diabetes

This study examines how participant-reported outcomes relate to residual beta cell function and metabolic control in youth newly diagnosed with type 1 diabetes, highlighting modest associations with glucose management but weaker links to beta cell preservation.
GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation
Posted inDiabetes & Endocrinology news Ophthalmology

GLP-1 Receptor Agonists and the Risk of Ischemic Optic Neuropathy in Type 2 Diabetes: Evidence from a Target Trial Emulation

This study evaluates the association between GLP-1 receptor agonists and ischemic optic neuropathy risk compared to SGLT2 and DPP-4 inhibitors, revealing a small but statistically significant increased risk with GLP-1RAs, particularly among older men with cardiovascular or eye conditions.
Exploring Low-Dose Antithymocyte Globulin Therapy in Type 1 Diabetes: Real-World Insights Using Modified Quantitative Response of C-Peptide
Posted inDiabetes & Endocrinology news

Exploring Low-Dose Antithymocyte Globulin Therapy in Type 1 Diabetes: Real-World Insights Using Modified Quantitative Response of C-Peptide

This article examines real-world data on low-dose antithymocyte globulin in type 1 diabetes, assessing beta-cell function via a novel C-peptide modified quantitative response (mQR). Findings suggest feasibility, safety, and potential clinical benefit in preserving endogenous insulin secretion.